Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.41 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574910 | 0.99 | MEN1 (0.74) | MEN1BLMKMT2ATHRBRECQL | |
| Bromide SCHEMBL30740862 | 0.98 | MEN1 (0.72) | MEN1BLMKMT2ATHRBRECQL | |
| Hydrochloric Acid SCHEMBL16295013 | 0.85 | MEN1 (0.98) | MEN1BLMKMT2ATHRBRECQL | |
| SCHEMBL14013408 | 0.84 | MEN1 (0.79) | MEN1BLMKMT2ATHRBRECQL | |
| SCHEMBL13525202 | 0.84 | MEN1 (1.00) | MEN1BLMKMT2ATHRBRECQL | |
| SCHEMBL14192841 | 0.82 | MEN1 (0.51) | MEN1BLMKMT2ATHRBRECQL | |
| SCHEMBL12192021 | 0.82 | MEN1 (0.74) | MEN1BLMKMT2ATHRBRECQL | |
| SCHEMBL17124185 | 0.81 | MEN1 (0.72) | MEN1BLMKMT2ATHRBRECQL | |
| SCHEMBL27310366 | 0.81 | MEN1 (0.66) | MEN1BLMKMT2ATHRBRECQL | |
| SCHEMBL14013407 | 0.80 | MEN1 (0.71) | MEN1BLMKMT2ATHRBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024109771-A1 | APPLICATION METHOD FOR EVALUATING MITOCHONDRION STATES OF LIVING GERM CELLS AND EARLY EMBRYO THEREOF BASED ON ORGANIC FLUORESCENT PROBE | 中国科学院深圳先进技术研究院 | 2024-05-30 | — | — | WO | claimed |
| WO-2023164252-A1 | ISOTHERMAL NUCLEIC ACID DETECTION ASSAYS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-31 | — | — | WO | claimed |
| CN-116024296-A | Application method for evaluating mitochondrial state of living germ cells and early embryo thereof based on organic fluorescent probe | 中国科学院深圳先进技术研究院 | 2023-04-28 | — | — | CN | claimed |
| US-11371085-B2 | Reagents and methods for isothermal chain reaction | MANCEBO RICARDO (US) | 2022-06-28 | — | — | US | claimed |
| US-12637489-B2 | Silicon containing modified nucleotide analogs | Singular Genomics Systems, Inc. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026107198-A1 | ANTIBODY BIOMARKER TO DIAGNOSE IDIOPATHIC INFLAMMATORY MYOPATHIES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026106440-A1 | MEDIUM COMPOSITION FOR IN VITRO FERTILIZATION AND/OR IN VITRO CULTURE OF AGED OOCYTES AND METHOD FOR IN VITRO FERTILIZATION AND/OR IN VITRO CULTURE USING SAME | 주식회사 미토이뮨테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107335-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISEASES BY INHIBITING EFHD1 | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12630808-B2 | Modified archaeal family b polymerases | Singular Genomics Systems, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| CN-122031933-A | Device for treating Alzheimer's disease | 深圳大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-11266673-B2 | Nucleotide derivatives and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220064697-A1 | AMPLIFICATION METHODS AND SYSTEMS FOR MERFISH AND OTHER APPLICATIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-03 | — | — | US | disclosed |
| EP-3955902-A1 | AEROSOLIZED COMPOSITIONS COMPRISING MITOCHONDRIA AND METHODS OF USE THEREOF | Children's Medical Center Corporation (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11254786-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | VANDERBILT UNIVERSITY (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2022032129-A1 | SINGLE-CELL LOCUS-SPECIFIC PROFILING OF EPIGENETIC MARKS | YALE UNIVERSITY (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2021263211-A9 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND CHIMERIC ANTIGEN RECEPTORS, AND METHODS OF USE IN IMMUNE SIGNALING MODULATION FOR CANCER IMMUNOTHERAPY | Houston Methodist Hospital (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022023331-A2 | USES OF SACCHARIDES FROM PRASINOCOCCALES | MICROA AS (NO) | 2022-02-03 | — | — | WO | disclosed |
| US-11236149-B2 | Microbe-binding molecules and uses thereof | PRESIDENT AND FALLOWS OF HARVARD COLLEGE (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254786-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | DSTN, PARN, CTSA | ACHE 1116/4885MEN1 1242/4885BLM 3584/4885 |
| US-12630808-B2 | Modified archaeal family b polymerases | SSU72, POLB, POLQ | ACHE 4310/4885MEN1 3513/4885BLM 67/4885 |
| US-12637489-B2 | Silicon containing modified nucleotide analogs | NSUN2, POLR2H, POLH | ACHE 4716/4885MEN1 2394/4885BLM 177/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | ACHE 4768/4885MEN1 4445/4885BLM 568/4885 |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | DNMT3A, POLB, POLM | ACHE 3386/4885MEN1 2077/4885BLM 55/4885 |
| US-11266673-B2 | Nucleotide derivatives and methods of use thereof | POLRMT, NSUN2, NUDT1 | ACHE 3713/4885MEN1 3223/4885BLM 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.